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Abstract
The present study was conducted in pregnant rhesus monkeys to determine the rapidity
and extent to which BPA reaches the fetal compartment following oral ingestion, and the 24-
hr fate of BPA. To assess metabolism changes during the course of pregnancy, we com-
pared BPA biotransformation during the second and third trimesters in the same animals,
measuring the levels of sulfated, gluronidated, and free BPA in maternal serum, amniotic
fluid, and fetal serum. All animals showed measurable unconjugated and conjugated BPA in
the fetal compartment and slow clearance compared to maternal serum. There were higher
levels of BPA-G in amniotic fluid at 150 days gestation compared to 100 days gestation, as
well as higher levels of BPA-G than BPA-S. We also monitored 3H-BPA (and metabolites) in
key tissues and excreta from a mother and fetus and from a non-pregnant female. The elimi-
nation of radioactivity was rapid, but residues were still detectable 24 hr after dosing in all tis-
sues analyzed. These data suggest that, in primates, rapid maternal processing of BPA
does not alleviate the risk of exposure to the developing fetus. This study elevates concerns
about levels of current BPA human exposure from potentially a large number of unknown
sources and the risks posed to developing fetuses.
Introduction
The use of bisphenol A (BPA) in a wide range of consumer products brings humans into daily
contact with this chemical, and data from biomonitoring studies suggest that BPA and its
metabolites can be detected in nearly all human subjects [1]. Indeed, epidemiological data sug-
gest that, in the US, exposure to BPA is nearly constant [2]. Despite the pervasiveness of
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exposure, our understanding of the levels and routes by which we are exposed and how our
bodies metabolize BPA remains woefully inadequate [3].
It was assumed for many years that the major route of human exposure to BPA is through
the ingestion of contaminated food and beverages. Data from numerous biomonitoring stud-
ies, however, have reported far higher levels of unconjugated BPA in serum than expected
based on the assumption that BPA is absorbed from the gastrointestinal tract [3–4], and grow-
ing evidence suggests that non-oral routes contribute significantly to human BPA exposure
[2–3,5–7]. This is important, because it means that inferences about the levels and duration of
human exposure to unconjugated (bioactive) BPA that have been based on the assumption
that BPA is rapidly conjugated and inactivated significantly underestimate human exposure.
In the rodent, dog and monkey, intra-gastric gavage results in relatively rapid conjugation
of BPA and bioavailability of less than 1% [8–10]. In monkeys, however, BPA delivered in a
piece of fruit resulted in BPA bioavailability of ~7%, indicating higher than expected unconju-
gated BPA in serum relative to bioavailability after intra-gastric gavage. This difference was
attributed to the monkeys slowly chewing the fruit, and some monkeys not swallowing all of
the fruit for an extended period of time [7,11].
Data from direct studies in human adults also provide evidence that the route of exposure
influences the levels and duration of exposure to bioactive BPA. The first metabolism study in
humans involved a single dose administered in a capsule [12]. Although the assay was insuffi-
ciently sensitive for measurement of the unconjugated compound, levels of conjugated BPA
led authors to conclude that BPA is rapidly conjugated and excreted in humans. This is consis-
tent with data from experimental studies, since capsule delivery, like gavage, should result in
low bioavailability BPA in serum. In contrast, as in monkeys fed BPA in a piece of fruit [11],
the delivery of BPA in a cookie resulted in higher BPA bioavailability in humans [13]. Interest-
ingly, however, a recent study administering BPA in soup led to low bioavailability [14], sug-
gesting that the rapidity with which the chemical is swallowed influences exposure. This is
consistent with the finding that residence time in the mouth is a critical variable that affects
bioavailability in dogs [9], and suggests that buccal/sublingual absorption attenuates the rapid
“first-pass” metabolism of gavage-administered BPA.
A rapid increase in unconjugated BPA in serum also has been reported from transdermal
absorption from handling thermal receipt paper. Importantly, levels of bioactive BPA were
sustained, with higher bioactive than conjugated levels persisting in serum for over 90 min fol-
lowing exposure [6]. Thus, based on the available data from human and experimental studies,
entry of BPA into the body by sublingual, transdermal or respiratory exposure should lead to
higher and sustained levels of bioactive BPA in serum than predicted on the basis of intra-gas-
tric gavage.
This is sobering, given that the low levels induced by oral BPA exposure have been reported
to significantly impact the fetus, altering the development of a wide range of organ systems,
including brain, reproductive tract, lung, and mammary and prostate glands, and leading to
behavioral changes, reduced fertility, metabolic disorders and cancer in adult laboratory ani-
mals [15–17]. Although most studies reporting effects have used rodents, recent studies in the
rhesus monkey provide evidence of a similar wide range of effects in response to blood levels
of unconjugated BPA below those reported in human biomonitoring studies [3,11,18–23].
Concerns about interspecies differences in the metabolic fate of BPA in mice and primates
[24] have made the rhesus monkey a critical model in understanding the pharmacokinetics of
BPA. BPA readily crosses from maternal blood into the fetal compartment in the monkey
[7,10], and a single bolus intravenous (IV) dose has been reported to produce measurable lev-
els of unconjugated BPA in fetal blood in less than an hour [10]. Further, a 50-day exposure
using daily oral dosing or continuous exposure via implanted Silastic capsules resulted in
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detectable unconjugated BPA in fetal serum and demonstrated that BPA pharmacokinetics are
altered by pregnancy and change over the course of gestation [7].
Assessing the risk posed by fetal exposure is not only complicated by metabolic differences
due to exposure route and stage of gestation, but also by new concerns about BPA metabolites.
The two major metabolites, BPA-monosulfate (BPA-S) and BPA-glucuronide (BPA-G) have
been widely assumed to be both stable and to have no bioactivity. Further, the stability of these
metabolites in the body is unclear: Like estrogen, which undergoes sulfation and desulfation,
particularly during pregnancy [25] sulfated BPA could act as a “reserve”, yielding bioactive BPA
following hydrolysis. In addition, many tissues contain ß-glucuronidases that can deconjugate
glucuronidated metabolites [26–27], and deconjugation of BPA-G by ß-glucuronidase has been
reported in the rat caecum; enterohepatic circulation of BPA in rodents is well established [28].
The present study was conducted in the pregnant rhesus monkey to determine the rapidity
and extent to which BPA reaches the fetal compartment following oral ingestion, and the
24-hr fate of BPA in the pregnant female. To assess metabolism changes during the course of
pregnancy, we compared BPA biotransformation during the second and third trimesters in
the same animal, measuring the levels of sulfated, gluronidated, and free BPA in maternal
serum, amniotic fluid, and fetal serum. We also monitored 3H-BPA (and metabolites) in key
tissues and excreta from the mother and fetus. Our data suggest that, in primates, rapid mater-
nal processing of BPA—even when it is orally ingested—does not alleviate the risk of exposure
to the developing fetus.
Materials and Methods
Monkeys. Five adult female rhesus macaques (Macaca mulatta) were housed at the California
National Primate Research Center (CNPRC). Animals were caged individually with a 0600–
1800 hours light cycle and at a temperature maintained between 25–27˚C. Cage size depends
on animal weight. Animals weighing less than 10kg were in a 4.3 square foot cage measuring 24
(L) x 27 (D) x 32 (H). Animals that were between 10kg and 15 kg were housed in a 6.4 square
foot cage measuring 34 x 27 x 32. No animals exceeded 15 kg. Animals were fed a diet of Purina
Monkey Chow and water ad libitum. Seasonal produce, seeds, and cereal were offered as sup-
plements for environmental enrichment. Cages were made of stainless steel, and water was
delivered to each cage by rigid PVC pipes and a “lixit” device. A wide array of enrichment is
available at CNPRC including manipulation, food and visual/auditory activities. All food items
were fresh and cage enrichment devices were determined to not be made of BPA-containing
plastic to minimize any possible BPA exposure other than treatments. Only females with a his-
tory of normal menstrual cycles were selected for this study. Females ranged in age from 6 to
13 years. Four females were time-mated according to standard CNPRC procedures. Pregnancy
was detected by ultrasound and an estimated day of conception (day 0) was assigned at the
time of pregnancy detection based on the timed mating schedule [29]. At approximately 40
days gestation the sex of the conceptus was determined using established protocols and those
dams with female fetuses were selected for the study (N = 4). Animal protocols were reviewed
and approved by the Institutional Animal Care and Use Committee at the University of Cali-
fornia, Davis prior to study initiation; all studies were conducted in accordance with the U.S.
National Institutes of Health Guide for the Care and Use of Laboratory Animals.
BPA Dosing and Sample Collection
Pharmacokinetic study
Oral non-labeled BPA (400 μg/kg) was given daily to three pregnant females from approxi-
mately 100 to 150 days gestation (term ~165±10 days). The BPA dose was dissolved in a small
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(100–150 μL) volume of ethanol and administered in a piece of dried fruit. On days of blood
and amniotic fluid sample collection BPA was administered via nasogastric intubation to pre-
vent a possible delay in absorption due to cheek pouch food storing by some monkeys [7,11].
On sample collection days, maternal blood, amniotic fluid, and fetal blood were collected
from Telazol anesthetized animals in sequence; maternal blood was obtained from a peripheral
vessel and amniotic fluid and fetal blood (cardiocentesis) were collected under ultrasound-
guidance using well-established methods [29]. Pre-treatment baseline values were obtained at
approximately 95 days gestation (second trimester) and prior to the first maternal dose of
BPA. At approximately 100 days gestation daily BPA dosing commenced and, following
administration of the first dose, maternal and fetal samples were collected at 1, 2, and 4 hr
post-administration. Animals were returned to housing and monitored by colony staff care-
fully after collection procedures. Near term (approximately 150 days gestation), the final BPA
dose was administered, dams were anesthetized and samples were collected at 1, 2, and 4 hrs
post-administration, with the final collection coordinated with the surgical removal of the ges-
tational sac for fetal tissue collection. For gestational sac removal, animals were first anesthe-
tized with Telazol followed by inhalation anesthesia during surgery, according to established
CNPRC procedures. All dams were returned to the colony post-hysterotomy, monitored by
colony personnel and administered analgesics as necessary.
3H-BPA metabolic balance study
Nasogastric intubation was used for two additional adult females (one pregnant and one non-
pregnant) who received a single oral dose of 3H-BPA, corresponding to 2.50 MBq (6.76 x 10–
11 mCi or 7.78 μg BPA/kg BW) and 1.42 MBq (3.84 x 10–11 mCi or 4.45 μg BPA/kg BW) for
the pregnant (approximately 140 days gestation) and the non-pregnant female, respectively.
For these animals, urine and feces were collected over a 24-hr period. Fluids, excreta, and tis-
sues were recovered and stored at-20˚C until radioactivity quantification. Cages were
washed with ethanol for radioactivity measurement and inclusion in the metabolic balance.
Collected samples were sent to the INRA Research Centre in Food Toxicology (TOXALIM,
Toulouse, France) for radioactivity quantification, extraction, and Radio-HPLC analyses in
compliance with international regulations.
Chemical Analysis
Chemicals
Radiolabeled bisphenol A ([3H]-bisphenol A, radiochemical purity 99.9% checked by radio-
High Performance Liquid Chromatography coupled to radioactivity detection (Radio-HPLC);
specific activity 299.7 GBq/mmol) was purchased from Moravek Biochemicals and Radioche-
micals (Brea, ST, USA). Monophase S, Flo-Scint II and Ultima Gold liquid scintillation cock-
tails were obtained from Perkin Elmer Life Sciences (Courtabœuf, France). All solvents were
of analytical grade and were purchased from Fisher Scientific (Illkrich, France). Ultrapure
water from Milli-Q system (Millipore, Saint Quentin en Yvelines, France) was used for HPLC
mobile phases.
Reference standards for BPA and BPA-d16 were purchased from Sigma (St Louis, MO)
while analytical grade standards for BPA sulfate, BPA glucuronide and 13C-BPA glucuronide
were provided by the National Toxicology Program. BPA-free water was purchased from
Aqua Solutions (Deer Park, TX) and analytical grade methanol and acetonitrile were obtained
from Honeywell Burdick and Jackson (Muskegon, MI). Stock solutions of standards and inter-
nal standards were prepared at 1 mg/mL, aliquoted to 1 mL portions in amber vials and stored
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at-80˚C. All calibration standards, ranging in concentration from 0.1 to 80 ng/mL, were pre-
pared from the stock solution by serial dilution in the appropriate matrix blank.
Pharmacokinetic studies
Analysis of BPA, BPA-G and BPA-S in amniotic fluid and serum was performed by liquid
chromatography-tandem mass spectrometry (LC-MSMS) as previously reported for serum
[30]. Using Agilent LC 1260- AB Sciex 5500, all three analytes were measured simultaneously
using electrospray ionization in negative polarity. Each analyte was monitored by multiple
reaction monitoring using two transitions, and BPA-d16 and 13C12-BPA mono-β-D-glucuro-
nide as internal standards: BPA- 227.0–133.1, 227.0–212.1; BPA glucuronide- 402.9–112.9,
402.9–226.9; BPA mono-sulfate-306.9–227.0, 306.9–212.1; BPA-d16- 241.0–142.2, 241.0–
222.1; and 13C12-BPA mono-β-D-glucuronide- 415.0–112.8, 415.0–239.1.
Amniotic fluid and serum samples were thawed and centrifuged at 1811 x g for 10 minutes
prior to their preparation for LC-MS/MS analysis by protein precipitation. Protein precipita-
tion was done by adding 750 μL 95:5 (v/v) acetonitrile: methanol to 250 μL amniotic fluid. The
resulting mixture was spun at 1811 x g for 5 minutes. The supernatant obtained after centrifu-
gation was then gently evaporated under a stream of nitrogen gas, after which it was reconsti-
tuted in 10% methanol for column injection.
A 25-uL aliquot of the extract was used for each replicate injection of the sample. An Agi-
lent Zorbax Extend-C18 column (4.6 x 100 mm, 1.8 μm) maintained at 50˚C was used for
chromatography. Chromatographic separation of the analytes was achieved by gradient elu-
tion using BPA-free water with 0.05% ammonium acetate (pH = 7.8) as mobile phase A and
methanol with 0.05% ammonium acetate (pH = 7.8) as mobile phase B. The elution gradient
employed was- 0–0.5 min = 30%B; 1 min = 75%B; 4 min = 100; 4–6 min = 100%B; and 6.01–
12 min = 30% B. The method’s limit of detection (LOD) for BPA and BPA glucuronide was
0.05 ng/mL while the method’s LOD for BPA mono-sulfate was 0.025 ng/mL. Quantitation of
each analyte was done by isotope dilution method using a 10-point calibration curve. Each
analyte has a limit of quantitation (LOQ) of 0.1 ng/mL Method precision and recovery were
validated for the assay and are reported in Tables 1 and 2. Method validation information has
been published [30]. Pretreatment samples of maternal blood, fetal blood and amniotic fluid
for each animal had no measurable BPA, thus verifying that sample contamination had not
occurred. The issue of sample contamination with chemicals, which are ubiquitous in the envi-
ronment, is not unique to BPA, and those experienced in developing assays are well aware of
the required controls to ensure the absence of contamination [3].
Radioactivity quantification
Liquid samples: radioactivity contained in plasma, urine, serum, bile, and amniotic fluid was
quantified by direct counting on a Packard scintillation counter (Model Tricarb 2100; Perkin
Table 1. Validated method precision established for the direct analysis of BPA and its primary metabolic conjugates in amniotic fluid using
LC-MS/MS.
Analyte Precision (% CV)
Within Run (n = 5) Between Run (n = 15)
Low 0.5 ng/mL Med 5 ng/mL High 20 ng/mL Low 0.5 ng/mL Med 5 ng/mL High 20 ng/mL
BPA 4.0 2.5 1.5 6.0 5.5 4.8
BPA-glucuronide 4.5 2.5 2.8 8.5 7.8 8.2
BPA-sulfate 2.5 2.3 1.8 5.5 5.2 5.0
doi:10.1371/journal.pone.0165410.t001
Maternal and Fetal Pharmacokinetics of Bisphenol A
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Elmer, Courtabœuf, France) using Packard Ultima Gold (Perkin Elmer) as the scintillation
cocktail. An external standard method was used for automatic quench correction. Tissues and
organs: tissues were homogenized by dilaceration before sampling for radioactivity quantifica-
tion. Aliquots of 0.2 to 0.5 g of wet tissue were combusted in a Perkin Elmer oxidizer (Model
307) using 15 mL Monophase S (Perkin Elmer) as scintillation cocktail. Three replicates were
analyzed for each sample.
Radio-HPLC analyses
Samples were analyzed on an Ultimate 3000 HPLC system (ThermoFisher, Villebon sur
Yvette, France) connected for radioactivity detection to a radiometric flow scintillation ana-
lyzer Flo-one A500 (Perkin Elmer). FloScint II was used as scintillation cocktail. Metabolite
separations were performed on a Zorbax SB-C18 column (5 μm, 250 x 4.6 mm, Agilent Tech-
nologies, Les Ulis, France) protected by a Kromasil C18 precolumn (5 μm, 10 x 4.6 mm). The
mobile phases were ammonium acetate buffer 20 mM, pH 3.5/acetonitrile: 95%/5% in (A) and
10%/90% in (B), respectively. Solvents were delivered at a flow rate of 1 mL/min as follows: 0
to 4 min 100% A; 4 to 6 min linear gradient from 100% A to 15% B, 6 to 16 min 15% B; 16 to
18 min linear gradient from 15% B to 25% B, 18 to 28 min 25% B; 28 to 30 min linear gradient
from 25% B to 30% B, 30 to 37 min 30% B; 37 to 39 min linear gradient from 30% B to 70% B;
39 to 50 min 70% B; 50 to 52 min linear gradient from 70% B to 100% B; 52 to 60 min 100% B.
In such conditions, BPA’s retention time (RT) was 43 min. Metabolites were quantified by inte-
grating the area under detected radioactive peaks.
Enzymatic hydrolyses and metabolites identification
Given the low BPA doses used and the high specific radioactivity of 3H-BPA, direct MS charac-
terization was not possible. Consequently, structural elucidation was carried out using bio-
chemical tools and confirmed by co-elution with authentic standards synthesized as previously
described by us [24,31]. ß-glucuronidase from E. coli and sulfatase from A. aerogenes (Sigma-
Aldrich, Saint Quentin Fallavier, France) were used to hydrolyze conjugated metabolites in
order to assess the formation of the BPA-G and BPA-S, respectively. ß-glucuronidase: enzyme
hydrolysis was conducted by incubating samples in 1 mL sodium acetate buffer (200 mM, pH
5) containing 500 International Units of E. coli ß glucuronidase, as specified by the supplier.
Sulfatase: samples were incubated with 1 mL Tris buffer (10 mM, pH 7.1) containing 1 unit of
A. aerogenes sulfatase as specified by the supplier. ß-glucuronidase and sulfatase incubations
were performed over 3 hr at 37˚C in a shaking water bath. Blank incubations were performed
without enzyme under the same conditions. At the end of the incubation period, proteins were
precipitated with 3 mL of MeOH, the supernatant was evaporated under a stream of nitrogen,
and the residue was solubilized in mobile phase A for HPLC analysis.
Table 2. Validated method recoveries established for the direct analysis of BPA and its primary metabolic conjugates in amniotic fluid using
LC-MS/MS.
Analyte Recovery (%)
Within Run (n = 5) Between Run (n = 15)
Low 0.5 ng/mL Med 5 ng/mL High 20 ng/mL Low 0.5 ng/mL Med 5 ng/mL High 20 ng/mL
BPA 90.5 94.5 94.5 88.0 94.5 93.0
BPA-glucuronide 87.5 90.4 92.0 84.5 89.0 90.2
BPA-sulfate 88.0 92.5 96.5 86.5 90.5 91.5
doi:10.1371/journal.pone.0165410.t002
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Statistical analysis
Comparison between values was achieved using the Student t-test.
Results
BPA, BPA-G and BPA-S in maternal and fetal serum at 100 and 150
days gestation
Levels of unconjugated BPA (Fig 1) were generally within a similar range in maternal and fetal
serum at both gestational time points assessed, with the exception of one monkey at gestation
day 100 that showed a spike in fetal serum unconjugated BPA 2 hours after maternal gavage,
that resulted in a 20-fold higher level in fetal serum compared to maternal serum. In addition,
samples from one monkey at the 100 day time point were damaged and thus, data from that
animal is not include; thus, standard errors were not calculated for Day 100.
Although levels of unconjugated BPA were generally similar in maternal serum and fetal
serum at gestation days 100 and 150 (Fig 1), differences in the levels of conjugates were evi-
dent. Maternal serum BPA-G and BPA-S were highest 1 hr after dose delivery and declined
over the 4 hr assessment period. In contrast, levels of conjugated BPA in fetal serum tended to
slightly increase between 1 and 4 hr after maternal dosing. Maternal and fetal serum levels of
BPA-G were generally in the range of 100-fold higher than levels of unconjugated BPA, with
highest ratios of glucuronidated to unconjugated observed at the 1 hr time point in maternal
serum and the 4 hr time point in fetal serum. The levels of BPA-S were 10–30 times lower than
BPA-glucuronide at the time points evaluated, but exhibited the same pattern as BPA-G, con-
tinuing to rise slightly through the 4 hr in fetal serum, while maternal serum levels declined. It
is important to note that maternal levels of both BPA-G and BPA-S were higher than fetal lev-
els at 1 and 2 hr after exposure, but not at the 4 hr time point.
The maternal and fetal serum and amniotic fluid levels of unconjugated BPA at 100 and
150 days gestation are shown in Fig 1. With the exception of one animal at 150 days, amniotic
fluid levels of unconjugated BPA remained relatively stable between 1 and 4 hr after maternal
Fig 1. Levels of unconjugated BPA, BPA-G and BPA-S in maternal (red line) and fetal (blue) serum and amniotic fluid
(black) at 100 (top panel, N = 2) and 150 days gestation (bottom panel, N = 3) following a single oral dose of BPA.
doi:10.1371/journal.pone.0165410.g001
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dosing. There were higher levels of BPA-G at 150 days gestation compared to 100 days gesta-
tion, as well as higher levels of BPA-G than BPA-S. Amniotic fluid had a range of unconju-
gated BPA of 0.15 to 1.71 ng/mL, BPA-G of 3.56 to 65.54 ng/mL and BPA-S of 0.01 to 6.66 ng/
mL. The pre-treatment collections of all samples at 100 days gestation were below the limits of
detection for unconjugated BPA, BPA-G and BPA-S.
Disposition of BPA over 24 hr after oral administration of 3H-BPA
An early peak of 3H in serum (T = 1 hr) was observed in both the pregnant and the non-preg-
nant monkey dosed with 3H-BPA (Fig 2). The elimination of radioactivity was rapid, but resi-
dues were still detectable 24 hr after dosing [~220 and 286 parts per trillion (ppt; pg/g) in the
pregnant and non-pregnant animal, respectively]. Direct radio-HPLC profiling could be car-
ried out in both animals up to 4 hr after dosing (Fig 2 & Table 3), confirming the presence of a
major peak identified as BPA-G based on retention time (Rt) comparison with the authentic
standard, as well as specific biochemical hydrolyses, followed by R-HPLC controls. Likewise,
we confirmed the presence of both the sulfate conjugate and parent compound in serum,
Fig 2. 0–24 hr serum levels of BPA residues measured in a pregnant (blue) and a non pregnant (orange) Rhesus macaque
dosed with 7.78 μg/kg and 4.45 μg/kg 3H-BPA, respectively. Results are expressed in pg/g (ppt) of BPA equivalents. A typical
radio-HPLC profile corresponding to the analysis of serum radioactivity is displayed at the top right of the figure.
doi:10.1371/journal.pone.0165410.g002
Maternal and Fetal Pharmacokinetics of Bisphenol A
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although both BPA-S and BPA accounted only for a minor part of the detected radioactivity
(Table 3).
In both 3H-dosed animals most of the radioactivity was excreted in urine, while fecal excre-
tion was extremely limited (Table 4). Additional radioactivity (12–13% of the 3H dose) was
recovered in cages, likely corresponding to urine that dried in cage pans. Despite the limited
fecal excretion, roughly 2% of the administered radioactivity remained in the gastrointestinal
tract of both animals 24 hr post-dosing, and nearly as much in bile (Table 4), corresponding to
high biliary residue concentrations of 146 and 277 ppb (parts per billion) for the non-pregnant
and the pregnant animal, respectively. In urine as well as in serum samples, only 2 metabolites
were detected in addition to the parent compound. BPA-S and parent (unconjugated) BPA
were present, but BPA-G was by far the predominant peak in urine (Table 3). Higher propor-
tions of both BPA and BPA-S were found in bile samples, where an additional doubly glucuro-
nide/sulfate conjugate of BPA was characterized through selective enzymatic hydrolyses and
subsequent R-HPLC analyses.
Table 5 summarizes levels of 3H residues in tissues at 24 hr, for the non-pregnant animal
and both the dam and fetus. BPA residues could be quantified in all tissues, and ranged from
Table 3. Respective radio-HPLC percentages of BPA glucuronide (BPA-G), BPA sulfate (BPA-S), unconjugated BPA, and a double glucuronide/
sulfate conjugate of BPA (G-BPA-S, bile only) in monkey serum, bile, and urine samples. A = non pregnant animal. B = pregnant animal.
Sample Animal Time (hr) BPA-G BPA-S BPA G-BPA-S Total
Serum A 0.5 87.7 4.5 2.1 94.3
1 89.2 3.8 3.3 96.3
2 84.2 2.6 5.7 92.5
4 87.3 4.8 2.5 94.6
Serum B 0.5 94.5 3 0.9 98.4
1 96.7 1.2 0.5 98.4
2 86 3.8 1.5 91.3
4 84.8 4.2 2.1 91.1
Bile A 24 58.4 10.1 12.5 10.5 91.5
B 24 61.8 8.1 7.5 12.2 89.6
Urine A 0–24 87.4 0.39 4.79 92.6
B 0–24 91.9 0.49 3.39 95.8
Fetus (B) 24 87.2 0 0.97 88.17
doi:10.1371/journal.pone.0165410.t003
Table 4. 3H-BPA 24 hr metabolic balance in a non-pregnant (A) and a pregnant (B) monkey orally
dosed with 4.5 and 7.8 μg/kg BW 3H-BPA, respectively. Results are expressed in percentage of the
administered dose.
Non-Pregnant (A) Pregnant (B)
Urine 83.05 90.64
GI Tract 1.58 2.88
Bile 1.83 1.93
Feces 0.11 0.001
Tissues (sum of) 0.23 0.046
Placenta 0.009
Fetus 0.001
SAmniotic fluid N.A 0.025
TOTAL 86.79 95.53
Cages 12.33 13.12
doi:10.1371/journal.pone.0165410.t004
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10 to 100 ppt. Higher levels were measured in the kidney and the liver, as well as in the uterus
and ovaries in both the pregnant and non-pregnant female. For the pregnant monkey, the
overall transfer of BPA residues at 24 hours to the fetus was less than 0.03% of the dose, 5/6th
of which was located in the amniotic fluid, and an additional 0.01% in the placenta. However,
radioactivity at 24 hours could be detected in all fetal tissues and fluids, ranging from 22.5 ppt
(brain) to 136.7 ppt (lung). The level of 3H residues measured in fetal serum was 119 ppt. Only
BPA-G and parent BPA were detected in fetal urine collected from the bladder and amniotic
fluid. In fetal urine, BPA-G was by far the predominant metabolite, and only traces of parent
BPA (1%) were detected (Table 3). Conversely, although BPA-G was the major residue in
amniotic fluid (182 ppt), a greater contribution of parent BPA (24.5 ppt) was observed in this
sample.
Discussion
Data from numerous human biomonitoring studies suggest far higher levels of serum uncon-
jugated BPA than expected on the basis of experimental studies using gavage administration
[32]. Further, while there is a considerable information on the pharmacokinetics of BPA in
rodents, information on humans are very limited [3,33]. Studies comparing BPA pharmacoki-
netics in pregnant and non-pregnant women are not possible, as administration of BPA during
pregnancy would not be ethically acceptable given the large amount of data showing a wide
range of impacts to developing fetuses [15–17,30,34]. Given the importance of understanding
human exposure levels, routes of exposure, and how our bodies metabolize BPA—especially
during pregnancy—we turned to a nonhuman primate model, the rhesus monkey. The data
presented here examine the levels of BPA and both major conjugates, BPA-glucuronide
(BPA-G) and BPA sulfate (BPA-S) in maternal and fetal compartments during mid- and late
gestation after gavage administration. Importantly, our data provide the most accurate assess-
ment of BPA levels to date, since the LC-MSMS assay used to measure BPA has been shown to
be accurate and contamination free in a NIH-sponsored round-robin study involving multiple
laboratories [30]. This is critical given previous claims that the detection of unconjugated BPA
Table 5. 3H residue levels in adult and fetal tissues and fluids, at 24 hr, in an adult female Rhesus macaque (A) orally dosed with 4.5 μg/kg BW
3H-BPA, and in a gravid dam (B) orally dosed with 7.8 μg/kg BW 3H-BPA, and the respective fetus. Results are expressed in ppt (ng/g) of BPA equiva-
lents. Percent (%) of dose is the percentage of the administered dose.
Animal/Dose Animal A 4.45 μg/kg Animal B 7.77 μg/kg
Dam Fetus
% of Dose ppt % of Dose ppt % of Dose ppt
Liver 0.167 396.7 0.0302 146.5 0.00081 59.8
Kidney 0.031 405.1 0.0124 216.2 0.00031 104.6
Uterus 0.014 265.3 0.0287 165.2 0.00002 78.7
Ovaries 0.0014 595.8 0.0004 750.3 0.00001 84.3
Brain 0.0047 21.6 0.0019 13.2 0.00141 22.5
Heart 0.0022 20.6 0.0006 13.2 0.0001 59.9
Lung 0.0009 43.8 0.0018 29.5 0.00171 136.7
Adrenals 0.0008 97.7 0.0001 58.0 0.00001 60.7
Spleen 63.8 0.0004 47.3 0.00003 42.3
Skin 48.2 65.6 96.3
Muscle 49.8 28.3 50.1
Fat (Abdominal) 27.5 14.6 74.7
Fat (Cutaneous) 11.7 15.1
doi:10.1371/journal.pone.0165410.t005
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in serum is merely a reflection of BPA contamination during either sample collection or assay
[10]. Thus, the presence of unconjugated BPA in this carefully controlled analysis supports the
contention that the presence of bioactive BPA in human tissues is real based on biomonitoring
studies in which controls for contamination were included [3]. These conclusions are sup-
ported as well by our parallel experiments using 3H-BPA, demonstrating the presence of par-
ent (non-conjugated) BPA in all fluids and extracts examined by radio-HPLC.
Adoption of the serum method and its validation in amniotic fluid facilitated the direct,
simultaneous analysis of BPA and its two major metabolites in amniotic fluid. To our knowl-
edge, our method is the first to achieve sensitivities below 1 ng/mL for all three analytes in
amniotic fluid [35]. This allowed for an accurate and more sensitive measurement of BPA and
its metabolites in this biological compartment, enabling better and longer tracking of these
analytes in pharmacokinetic studies.
Our studies of pregnant rhesus females were carried out at two gestational stages, late sec-
ond trimester (100 days gestation) and near term (150 days gestation). Our findings confirm
that BPA delivered by gavage is readily transferred to the fetal compartment. The collection of
matched maternal and fetal samples over a 4 hr period at two different stages of gestation
allowed us to directly compare levels in maternal and fetal serum as well as amniotic fluid. Fur-
ther, pharmacokinetic analysis based on the monitoring of unconjugated BPA, as well as
BPA-G and BPA–S was validated by the results of a 3H-BPA based study run in parallel, since
no other major metabolite could be detected in serum or amniotic fluid samples.
The levels of unconjugated and conjugated BPA in maternal serum in this study were pre-
dicted based on our previous study of orally dosed rhesus monkeys [7], and a daily dose of
400 μg/kg/day produced the expected levels of bioactive BPA in maternal serum. Importantly,
the levels of unconjugated BPA in this study were similar to those measured in numerous
human studies [32,36]. Thus, levels of BPA measured in fetal serum and amniotic fluid should
be directly relevant to levels in pregnant women.
An important aspect of the current study is that, on days when sampling occurred, BPA
was given via gavage to remove the influence of sublingual absorption that enhances the con-
centration of unconjugated BPA in serum [9]. Therefore, the data in Fig 1 show a much higher
peak level of maternal BPA-G than in our previous study in which BPA was administered in
dried fruit [7]. Gavage dosing maximizes first-pass metabolism in the liver, thus resulting in
lower unconjugated and higher BPA-G levels than would be expected from any other route of
exposure [6,9]. Further, although a rapid reduction in BPA-G in maternal blood over the 4 hr
sampling period was evident at both 100 and 150 days gestation, measurable levels of conju-
gated BPA in the fetal compartment (serum and amniotic fluid) not only were present at 1 hr
but persisted and even slightly increased over the 4 hr period. This suggests that fetal BPA
exposure following a single oral administration persists far longer than previously thought,
and is consistent with the slow rate of BPA-G clearance from fetal serum recently reported in
sheep [27]. These data suggest that if, as predicted [2], BPA exposure for the US population is
continuous and from multiple routes, fetuses would be expected to have higher levels of BPA
for longer periods of time relative to their mothers.
Although levels of BPA-G and BPA-S were lower in fetal serum and amniotic fluid than in
maternal serum, they did not show the rapid decrease that occurred in maternal serum. These
results are similar to findings from studies in the pregnant ewe and mouse that suggest these
BPA metabolites are trapped in the fetal compartment [24,35]. They differ, however, from our
previous finding that levels of conjugated BPA in fetal serum and amniotic fluid were dramati-
cally higher than in maternal serum on both 100 and 150 days gestation when pregnant mon-
keys were administered BPA chronically via subcutaneous Silastic implants, a method of
administration chosen to more closely mimic chronic BPA exposure. We previously reported
Maternal and Fetal Pharmacokinetics of Bisphenol A
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an inverse relationship between the concentration of unconjugated BPA and the ratio of con-
jugated:unconjugated BPA in maternal serum [7]. Routes of exposure that lead to a high ratio
of conjugated:unconjugated BPA, such as intra-gastric gavage, will thus lead to lower concen-
trations of unconjugated BPA that can pass from maternal to fetal blood; transplacental trans-
port of BPA-G from maternal to fetal compartments does not appear to occur [35]. Thus,
although the current findings from rhesus monkeys are relevant to humans, they likely under-
estimate actual human fetal exposure, since much of human exposure is thought to be by non-
oral routes that result in dramatically higher serum unconjugated BPA relative to the oral or
intra-gastric routes [1–2,6].
In parallel with the pharmacokinetic study, our study of the metabolic fate of 3H-BPA
administered by gavage to a non-pregnant and third trimester (140 days) pregnant female con-
firmed the rapid plasma peak (1 hr) of BPA residues in serum, and the persistence of detectable
residues up to 24 hr post-dosing. The predominance of BPA-G in serum and presence of
minor quantities of the sulfate conjugate and unconjugated BPA were confirmed and, as
expected, BPA residues (metabolites and parent compound) were extensively excreted in
urine, with very limited fecal excretion (below 0.2% of the administered dose). However, the
persistence at 24 hr of significant amounts of radioactivity in the gastrointestinal tract (~2% of
the administered dose) and in bile (similar quantities) provides strong evidence of enterohepa-
tic cycling of BPA residues. This has been well described in nonpregnant animals in both
rodents and primates [37–39]. Radio-HPLC profiling of bile extracts demonstrated the pres-
ence of BPA-G (major metabolite), parent BPA, BPA-S, as well as a bile-specific doubly conju-
gated metabolite (ca. 10% each). The three conjugates are expected to be cleaved back into the
parent compound at the level of the intestinal tract, primarily by bacterial enzymes [40] and
subsequently reabsorbed, contributing to the measurable levels of residues detected at 24 hr in
tissues and in the fetal compartment.
At 24 hr, all tissues assessed contained measurable amounts of radioactivity, corresponding
to 0.3% of the total administered dose. In adults, residual levels of 3H-BPA in tissues ranged
from 10–100 ppt, with the exception of the liver and kidney (150–400 ppt). In addition, the
adult uterus and ovaries (200–700 ppt) were obvious targets of BPA. Although prior experi-
mental evidence suggested that the ovary is strongly targeted [16], our data provide the first
clear evidence that BPA does in fact track to this tissue in nonhuman primates. Further,
although BPA residues have previously been demonstrated to be present at 24 hr in the uterus
and ovaries of exposed mice [24], in this species, the levels were lower than those measured in
mouse liver.
This species difference in reproductive tissue vs. liver may reflect the higher levels of circu-
lating estrogen in primates, including humans. For example, during gestation, levels in mice
peak at around 60 pg/mL [41] compared to primate levels of 500 pg/mL or more [42] and
potential differences in receptor density and affinity and membrane characteristics may also
affect relative binding sites for BPA.
However, the differences between rodents and primates in maternal serum estradiol are
complicated by the fact that rodent fetuses produce the estrogen-binding plasma protein
alphafetoprotein at high levels, which results in a much lower (about 10-fold) percent free
serum estradiol concentration (the bioactive fraction) in fetuses relative to adults [43]. In con-
trast, in rhesus monkeys and women, sex hormone binding globulin is produced in the mater-
nal but not the fetal liver, so total serum estradiol concentration is higher in the primate
mother relative to the fetus [44], which is the opposite of what occurs in rodents [45]. This
results in a similar serum concentration of free (bioactive) estradiol in the rodent and primate
fetus even though there is a marked difference in total serum estradiol.
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The 3H-BPA study, also confirms that BPA reaches fetal tissues and fluids in rhesus mon-
keys in which adverse effects in female offspring due to maternal BPA exposure have been
reported in experimental studies of the ovaries [18], uterus [20] mammary glands [19], and
brain, heart and lung [21–23]. In the current study, 3H-BPA residues were present in all tissues
and fluids in the single female monkey fetus examined, with concentrations ranging from 15
(fat) to 130 (lung) ppt. Furthermore, BPA residual levels in several tissues, including lung,
brain, and heart, were comparable in the fetus and dam. Because BPA interacts with both
nuclear estrogen receptors-α and –β as well as cell membrane–bound estrogen receptors [46],
relatively high receptor levels in these tissues might account for the residual levels. Specifically,
these tissues have been identified as having higher levels of estrogen receptor during fetal
development [47–48].
Conclusions
Monkeys in both the pharmacokinetic and metabolic fate study were administered oral BPA;
either as a single dose or a daily dose over the course of the study. All animals showed mea-
surable unconjugated and conjugated BPA in the fetal compartment and slow clearance com-
pared to maternal serum. As discussed above, quickly swallowed BPA is most rapidly
metabolized compared to other routes of exposure. Thus, the single oral dosing via nasogas-
tric tube protocol used on the sample collections days in this study represents the scenario
that would lead to the most rapid maternal metabolism and excretion and, presumably, the
lowest level of fetal exposure. Multiple exposures per day would potentially result in higher
fetal levels of BPA, and data from human studies suggest that BPA exposure is nearly con-
stant and results from multiple routes of exposure [1–2]. Further, because non-oral BPA
exposure leads to lower conjugated:unconjugated BPA ratios [7,11], it is likely these rhesus
studies have less unconjugated BPA fetal exposure that what is experienced in humans.
This study demonstrates that BPA is readily transferred from maternal to fetal serum and
amniotic fluid in primates after oral exposure. Furthermore, rapid processing and excretion of
BPA residues, with a predominance of glucuronic acid conjugation and major urinary excre-
tion, did not prevent substantial fetal exposure to unconjugated BPA. Importantly, the major
BPA metabolites, BPA-G and BPA-S, were found in the fetal compartment and persisted even
as maternal levels of these metabolites were declining. Lastly, the presence of small quantities
of both the sulfate metabolite and unconjugated BPA in most tissues and fluids examined sup-
ports the hypothesis of enterohepatic cycling of BPA residues. Taken together, these data sug-
gest that, in primates, rapid maternal processing of BPA does not alleviate the risk of exposure
to the developing fetus, even after oral exposure that results in markedly lower serum levels of
bioactive BPA relative to sublingual, transdermal or respiratory exposures. These findings ele-
vate concerns about levels of current BPA human exposure from potentially a large number of
unknown sources and the risks posed to developing fetuses.
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